Solifenacina: evidencia científica en el tratamiento de la vejiga hiperactiva

Cambronero Santos, Javier; Zungri Telo, Eduardo R.
Arch. esp. urol. (Ed. impr.) ; 63(3): 197-213, abr. 2010. mapa, tab
Artículo en Español | IBECS (España) | ID: ibc-85825

Documentos relacionados

  1. Antimuscarinic actions on bladder urothelium and lamina propria contractions are similar to those observed in detrusor smooth muscle preparations.
  2. Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M<sub>4</sub> muscarinic acetylcholine receptor.
  3. Impact of Bladder Wall Thickness on the Outcomes of Antimuscarinic Treatment in Women with Overactive Bladder.
  4. Overactive urinary bladder in elderly female patients: treatment specificities and drug interactions.
  5. Physostigmine should be used more readily for antimuscarinic toxicity: PRO.
  6. History and current trends in the treatment of idiopathic overactive bladder.
  7. Treatment of Ureteral Stent-Related Symptoms.
  8. What is the best first choice oral drug therapy for OAB?
  9. [The Efficacy of Fesoterodine Switched from Solifenacin for Overactive Bladder Patients].
  10. [The role of fixed dose combinations of inhaled cortikosteroids, long acting beta-2 agonists, and long acting muscarinic antagonists (ICS/LABA/LAMA) in the treatment of asthma].